In this Issue, Volume 7, Issue 6

Bromodomains have gained traction as important targets for treatment of a number of diseases including a number of cancers, multiple sclerosis, and cardiovascular diseases. Most drug discovery efforts to date have focused on the development of small molecule inhibitors of the BET subfamily of bromodomains, and BET inhibitors have progressed to clinical trials